Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Acrivon Therapeutics, Inc. - Common Stock (NQ: ACRV )

5.390 +0.150 (+2.86%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 5, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 42,335
Open 5.400
Bid (Size) 5.300 (8)
Ask (Size) 6.200 (1)
Prev. Close 5.240
Today's Range 5.290 - 6.360
52wk Range 3.411 - 25.47
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Why Daktronics Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Daktronics, Inc. (NASDAQ: DAKT) moved lower during Tuesday’s session following weak quarterly results. 
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga

Performance

YTD
-53.41%
-53.41%
1 Month
-5.11%
-5.11%
3 Month
-55.45%
-55.45%
6 Month
-55.23%
-55.23%
1 Year
-56.98%
-56.98%

More News

Read More
Acrivon Therapeutics Announces FDA has Granted Breakthrough Device Designation for ACR-368 OncoSignature Assay for Ovarian Cancer
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Analyst Ratings for Acrivon Therapeutics
Via Benzinga
Recap: Acrivon Therapeutics Q3 Earnings
Via Benzinga
Analyst Expectations for Acrivon Therapeutics's Future
Via Benzinga
Acrivon Therapeutics to Present at the Piper Sandler Annual Healthcare Conference
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Acrivon Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Acrivon Therapeutics Presents Data Demonstrating Capabilities of its AP3 Platform and ACR-368 OncoSignature Assay for Patient Responder Identification at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Acrivon Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Acrivon Therapeutics to Highlight its ACR-368 OncoSignature Test, Used in Ongoing Phase 2 Study to Treat Patients Based on Predicted Sensitivity to Monotherapy with its CHK1/2 Inhibitor ACR-368, at the Upcoming AACR-NCI-EORTC International Conference on
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Acrivon Therapeutics Announces ACR-2316, a Novel Dual WEE1 and PKMYT1 Inhibitor Development Candidate, Designed Using Acrivon’s AP3 Platform to Achieve Potent Single Agent Activity, as Demonstrated in Preclinical Studies
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Acrivon Therapeutics to Participate in Two Investor Conferences in September
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Acrivon Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For August 18, 2023
Via Benzinga
Acrivon Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Acrivon Therapeutics Announces the Appointment of Adam Levy, Ph.D., M.B.A., Experienced Biotech Investor Relations and Strategy Executive, to Senior Vice President and Head, Investor Relations and Corporate Affairs
From Acrivon Therapeutics, Inc
Via GlobeNewswire
7 Up-and-Coming Stocks to Buy for the Next Decade
Via InvestorPlace
Acrivon Therapeutics Announces the Appointment of Seasoned Biopharma Executive Charles Baum, M.D., Ph.D., a Recognized Leader in Clinical Precision Oncology, to its Board of Directors
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For June 2, 2023
Via Benzinga
Acrivon Therapeutics to Present at the Jefferies Healthcare Conference
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Acrivon Therapeutics Announces FDA Grants Fast Track Designation for Development of ACR-368 in Platinum-Resistant Ovarian Cancer and Endometrial Cancer
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Acrivon Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For May 8, 2023
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.